2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is chock-full of risky businesses that (supposedly) have what it takes to disrupt industries and reshape societies with their groundbreaking products and services. Of course, betting on those innovators-to-be often means investing in unprofitable or otherwise unproven companies, which is part of the reason why the ETF is down 68% over the past year.
But bear markets don't last forever, and within five years or so, many of Wood's picks will be either making their mark on history or going extinct. If those odds don't scare you off, read on as there are a pair of Cathie Wood growth stocks that do show promise for investors willing to take on greater-than-average risk.
As one of the leading biotech companies developing medicines using the much-hyped CRISPR-Cas9 gene editing technology discovered roughly a decade ago, CRISPR Therapeutics (NASDAQ: CRSP) isn't an investment for the faint of heart. Its clinical-stage programs are intended to treat or functionally cure illnesses like type 1 diabetes and even certain cancers. As if that wasn't enough, it's also working on a handful of pre-clinical gene editing programs that could theoretically cure hereditary diseases like hemophilia in living people.
Source Fool.com
